37. (WO2010026526) COMBINATION THERAPY FOR TUBERCULOSIS

PCT Biblio. Data | Description | Claims | National Phase | Notices | Drawings | Documents

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Machine translation

Query
FP:(%22tuberculosis%22)%20AND%20EN_ALL:nmr

Claims

1. Use of a compound of the formula or a pharmaceutically acceptable salt thereof:



(I) in combination with at least two anti-tuberculin agents in the manufacture of a medicament for the treatment of tuberculosis.

2. The use of claim 1 , wherein said at least two agents is selected from the group consisting of isoniazid, rifampin, rifapentine, rifabutin, pyrazinamide, ethambutol, streptomycin, kanamycin, amikacin, moxifloxacin, gatifloxacin, levofloxacin, ofloxacin, ciprofloxacin capreomycin, ethionamide, cycloserine, para-aminosalicylic acid, thiacetazone, clarithromycin, amoxicillin-clavulanic acid, imipenem, meropenem, viomycin, terizidone, TMC207, PA-824, OPC-7683, LL-3858 and SQ-109. 3. The use of claim 1 , wherein one of said at least two agents is selected from the group consisting of isoniazid, rifampin, rifapentine, rifabutin, pyrazinamide, moxifloxacin, gatifloxacin, levofloxacin, ofloxacin, ciprofloxacin, and ethambutol.

4. The use of claim 1 , wherein one of said at least two agents are selected from the group consisting of pyrazinamide, rifampin, rifapentine and isoniazid. 5. Use of a of a compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I) in combination with at least one anti-tuberculin agent in the manufacture of a medicament for treating tuberculosis after a subject has undergone an initial phase of treatment, for tuberculosis.

6. The medicament of claim 5 , wherein said at least one agent is selected from the group consisting of rifampin, rifapentine, rifabutin, pyrazinamide, ethambutol, streptomycin, kanamycin, amikacin, moxifloxacin, gatifloxacin, levofloxacin, ofloxacin, ciprofloxacin, capreomycin, ethionamide, cycloserine, para-aminosalicylic acid, thiacetazone, clarithromycin, amoxicillin-clavulanic acid, imipenem, meropenem, viomycin, terizidone, TMC207, PA-824, OPC-7683, LL-3858 and SQ-109. 7. The method of claim 5 or 6 wherein said active tuberculosis is selected from the group consisting of drug-sensitive tuberculosis, mono-drug resistant tuberculosis, multi-drug-resistant tuberculosis (MDR) and extensively drug-resistant tuberculosis (XDR).

8. A pharmaceutical composition comprising: i) a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

(ii) a therapeutically effective amount of at least one agent useful in the treatment of tuberculosis and,

(iii) one or more pharmaceutically acceptable carriers or vehicles.

9. The pharmaceutical composition of claim 8, wherein said at least one agent is selected from the group consisting of isoniazid, rifampin, rifapentine, rifabutin, pyrazinamide, ethambutol, streptomycin, kanamycin, amikacin, moxifloxacin, gatifloxacin, levofloxacin, ofloxacin, ciprofloxacin, capreomycin, ethionamide, cycloserine, para-aminosalicylic acid, thiacetazone, clarithromycin, amoxicillin-clavulanic acid, imipenem, meropenem, viomycin, terizidone, TMC207, PA-824, OPC-7683, LL-3858 and SQ-109.

10. The pharmaceutical composition of claim 8 or 9, wherein said at least one agent is selected from the group consisting of isoniazid, rifampin, rifapentine, rifabutin, pyrazinamide, moxifloxacin, gatifloxacin, levofloxacin, ofloxacin, and ethambutol.